RBC Capital Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $33

Benzinga · 1d ago
RBC Capital analyst Brian Abrahams maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $36 to $33.